Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2020. The report serves as a notification of transactions involving Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. Specifically, it details the vesting of conditional share awards granted in 2017 under the GSK Share Value Plan and the subsequent sale of shares to meet tax liabilities arising from these vesting events.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for the company. It exclusively reports on specific equity transactions for individual executives. Key transaction data includes:
- Share Classes: Ordinary Shares (ISIN: GB0009252882) and American Depositary Shares (ADSs) (ISIN: US37733W1053).
- Transaction Dates: Vesting occurred on February 17, 2020 (Ordinary Shares) and February 18, 2020 (ADSs). Tax-related sales occurred on the same dates.
- Transaction Prices:
- Ordinary Shares: Vesting at £0.00; Sales at £16.619.
- ADSs: Vesting at $0.00; Sales at $43.544.
- Notable Cash Proceeds: Ms. D. Conrad received a cash amount of £184,000 (less tax) in lieu of share transfer for one transaction.
Material Changes
The filing does not report material changes to the company's business operations, financial position, or market conditions compared to prior periods. The document is a routine regulatory disclosure of executive compensation vesting and tax withholding activities.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. The only unusual item noted is the specific mechanism of tax settlement for Ms. D. Conrad, where shares were converted to cash rather than transferred directly.
Investor Verification Checklist
- Verify the total number of shares sold by PDMRs to meet tax liabilities against the company's overall share buyback or treasury stock programs.
- Confirm the market price of GSK Ordinary Shares and ADSs on February 17 and 18, 2020, to validate the reported transaction prices (£16.619 and $43.544).
- Review the 2017 Share Value Plan terms to understand the vesting conditions that triggered these specific awards.
- Check subsequent filings to ensure all tax withholding obligations for the listed executives were fully settled.